

**Table S1. Characteristics of the Studies**

<b>First Author, Year</b>	<b>Country</b>	<b>Sites</b>	<b>Patient Population</b>	<b>Antibodies</b>	<b>Selection</b>	<b>Platelet Product(s)</b>	<b>Crossmatch Technique(s)</b>
<b>Prospective</b>							
Sayed D, 2011 <sup>14</sup>	Egypt	Single	Adult / pediatric acute leukemia	42% with HLA Ab		LR SDPs, ABO compatible	Flow PSIFT
Petz LD, 2000 <sup>8</sup>	USA	Single	Adult / pediatric refractory HT		Absence of non- immune factors	LR SDPs, ABO unselected, HLA identical preferred, but when not available, Ag- negative by LCT or XM- compatible units; if nothing available, random units	SPRCA
Ogden DM, 1993 <sup>15</sup>	USA	Single	Adult multiply- transfused HT	84% Plt.-reactive Ab		SDPs	LAA
O'Connell BA, 1990 <sup>16</sup>	USA	NS	Age-unspecified refractory acute	100% HLA Ab (90% with PRA $\geq$ 75%)	Absence of non- immune factors	Single pooled compatible PRP-RDPs	ELISA, SPRCA [Capture-P <sup>®</sup> ]

			leukemia				
Freedman J, 1988 <sup>31</sup> ,1989 <sup>17</sup>	Canada	NS	Adult / pediatric refractory HT	100% Plt.-reactive Ab	Absence of non- immune factors	Single pooled tested PRP- RDPs, ABO compatible	LCT, ELISA, Fluorometer PSIFT,  PRAT
Kickler TS, 1988 <sup>18</sup>	USA	NS	Age-unspecified refractory HT	100% LCTAb  (PRA $\geq$ 30%)	Absence of non- immune factors	SDPs, XM-compatible or  “least incompatible”	PRAT
Rachel JM, 1988 <sup>19</sup>	USA	Multiple	Age-unspecified, mostly-refractory HT	60% Plt.-reactive Ab  (75-80% in sub- analysis)		SDPs, ABO compatible	SPRCA [Capture-P <sup>®</sup> ]
Freedman J, 1984 <sup>32</sup>	Canada	NS	Adult HT	100% Plt.-reactive Ab  (mean PRA 58%)	Absence of non- immune factors	Single pooled tested PRP- RDPs, ABO compatible;  rotated un-XM, XM-  compatible, XM-  incompatible in all patients	PRAT (compared with  Fluorometer PSIFT)
Kakaiya RM, 1984 <sup>10</sup>	USA	NS	Adult / pediatric refractory HT	50% Plt.-reactive or  HLA Ab	Refractoriness  identified in  absence of non-	SDPs, ABO matched  preferred, HLA selected  when available	ELISA, Microscopy PSIFT, LCT,  AHG-LCT

					immune factors		
Brand A, 1978 <sup>33</sup>	Netherlands	Single	Age-unspecified refractory AA / AML	100% LCTAb (median PRA 60%)	Absence of non-immune factors	SDPs, ABO unselected, HLA selected and LCT XM-negative	Microscopy PSIFT
<b>Retrospective</b>							
Wiita AP, 2012 <sup>20</sup>	USA	Single	Refractory XM recipients (89% HT / 11% other)	96% Plt.-reactive Ab		SDPs, ABO compatible	SPRCA
Levin MD, 2004 <sup>21</sup>	Netherlands	Single	Age-unspecified lymphoma / leukemia	9-13% Plt.-reactive Ab		LR pre-pooled BC-RDPs, ABO matched	Flow PSIFT (compared with in vivo PSIFT, PSIFT and HLA ELISA)
Gelb AB, 1997 <sup>22</sup>	USA	Single	Adult / pediatric refractory HT	100% Plt.-reactive Ab (mean SPRCA PRA 40%)		SDPs	SPRCA [Capture-P <sup>®</sup> ]
Kohler M, 1996 <sup>23</sup>	Germany	NS	Age-unspecified HT	22% Plt.-reactive Ab	Absence of non-immune factors	LR SDPs, ABO matched or compatible, LCT XM-	Flow PSIFT, Flow LIFT, LCT (compared with MAIPA and LCT)

						negative and HLA selected preferred	
Sintnicolaas K, 1996 <sup>24</sup>	Netherlands	Single	Adult refractory or assumed refractory HT	93% HLA / 3% HPA Ab	Refractoriness identified in absence of non- immune factors	SDPs, ABO unselected, 70% HLA identical, 30% BX or C matches (only BX/Cs LR)	Flow PSIFT (compared with MAIPA XM)
Gates K, 1994 <sup>25</sup>	USA	Multiple	Adult refractory HT	100% Plt.-reactive Ab	Absence of non- immune factors	SDPs, sets of HLA XM selected or crossmatched, ABO compatible preferred	Flow PSIFT (compared with PAIFT, LCT and AHG-LCT)
Chow MP, 1991 <sup>34</sup> and 1992 <sup>26</sup>	China	Single	Adult / pediatric refractory HT	100% LCTAb (>20% PRA)		SDPs, ABO unselected, some HLA selected	LCT, Microscopy PSIFT
McFarland JG, 1987 <sup>35</sup>	USA	NS	Age-unspecified, refractory HT			SDP, ABO unselected, HLA selected	Microscopy PSIFT, LCT, PRAT, <sup>51</sup> Cr release
Heal JM, 1987 <sup>27</sup>	USA	Single	Adult / pediatric refractory HT	100% Plt.-reactive Ab	All had non- immune factors	SDPs, ABO unselected, HLA selected	ELISA

Kickler TS, 1985 <sup>36</sup>	USA	Single	Age-unspecified refractory HT	100% LCTAb (>30% PRA)	Absence of non- immune factors	SDPs, HLA selected, ABO compatible preferred	PRAT
Ware R, 1984 <sup>37</sup>	USA	Single	Adult / pediatric refractory HT	100% LCTAb	Absence of non- immune factors	SDPs, most HLA selected	Microscopy PSIFT, PRAT
Yam P, 1984 <sup>28</sup>	USA	Single	Age-unspecified refractory HT		Absence of non- immune factors	SDPs, mostly ABO compatible, HLA selected	Staph Protein A PRAT (compared with Microscopy PAP)
Kickler TS, 1983 <sup>29</sup>	USA	Single	Adult / pediatric refractory HT	100% LCTAb (median PRA 41%)	Absence of non- immune factors	SDPs, HLA selected, ABO compatible preferred	PRAT, LCT
<b>Prospective / Retrospective</b>							
Rebulla P, 2004 <sup>30</sup>	Italy	Single	Adult refractory HT	100% Plt.-reactive Ab (median PRA 100%)		LR SDPs and non-LR PAS- suspended, compatible BC- RDPs	SPRCA [Capture-P <sup>®</sup> ]
Skogen B, 1995 <sup>38</sup>	Norway	Single	Age-unspecified HT	Subset alloimmunized (PRA 46 – 76%)	Subset with absence of non- immune factors	SDPs for refractory alloimmunized patients., pooled BC-RDPs for non- alloimmunized patients	Flow PSIFT (compared with PAIFT)

Moroff G, 1992 <sup>7</sup>	USA	Multiple	Adult refractory HT	45% LCTAb	Absence of non-immune factors	SDPs, sets of HLA selected or XM, ABO compatible preferred	ELISA, Microscopy PSIFT, PRAT
Lane D, 1990 <sup>39</sup>	Canada	NS	Adult / pediatric HT	92% of tests LCTAb negative		SDPs, ABO identical, XM compatible and HLA selected preferred	SPRCA
Bowen TJ, 1986 <sup>40</sup>	Canada	Multiple	Adult refractory HT	100% LCTAb (median PRA 92%)		SDPs, ABO unselected, HLA selected	LCT, Microscopy PSIFT, ELISA
Filip DJ, 1976 <sup>41</sup>	USA	Single	Age-unspecified refractory HT	100% HLA Ab	Absence of non-immune factors	SDP, ABO unselected	LCT, SRA, PF3 Assay, Aggregometry

Abbreviations used in all tables:

AA = aplastic anemia; Ab = antibody; AHG-LCT = antihuman globulin augmented lymphocytotoxicity test; AML = acute myeloid leukemia; BC =buffy coat; Cr = chromium; CV = coefficient of variation; ELISA = enzyme-linked immunosorbent assay; HLA = human leukocyte antigen; HPA = human platelet antigen; HT = hypoproliferative thrombocytopenia; LAA = latex agglutination assay; LCT = lymphocytotoxicity test; LIFT = lymphocyte immunofluorescence test; LR = leukoreduced; MAIPA = monoclonal antibody immobilization of platelet antigen assay; NA = not applicable; NS = not stated; PAIFT = platelet adhesion immunofluorescent test; PAP = peroxidase anti-peroxidase; PAS = platelet additive solution; PF3 = Platelet Factor 3; Plt = platelet; PSIFT = platelet suspension immunofluorescence test; PRA = percent reactive antibody; PRAT = platelet radioactive antiglobulin

test; PRP = platelet rich plasma; RDP = random donor (whole blood-derived) platelet; SDP = single donor (apheresis) platelet; SPRCA = solid-phase red cell adherence assay; SRA = serotonin release assay; XM = crossmatch

**Table S2. Quality of Studies**

<b>First Author, Year</b>	<b>Source of Sample Appropriate?</b>	<b>Sampling Method Appropriate?</b>	<b>Sample Size Predetermined?</b>	<b>Eligibility Criteria Clearly Defined?</b>	<b>Control Group Acceptable?</b>	<b>Comparable Characteristics?</b>	<b>Clear Definitions of Outcomes?</b>	<b>Blinded Outcome Assessment?</b>	<b>*Quality Control?</b>	<b>Proportion of Missing Data?</b>	<b>Confounding Factors Analyzed?</b>
<b>Prospective</b>											
Sayed D, 2011 <sup>14</sup>	NS	Yes	No	No	NA	NA	Yes	No	Yes	No	Yes
Petz LD, 2000 <sup>8</sup>	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	Yes
Ogden DM, 1993 <sup>15</sup>	Yes	NS	No	No	NA	NA	Yes	No	NS	No	No
O'Connell BA, 1990 <sup>16</sup>	NS	NS	No	No	NA	NA	Yes	No	Yes	No	No

Freedman J, 1988 <sup>31</sup>	NS	NS	No	No	NA	NA	Yes	No	Yes	No	No
Kickler TS, 1988 <sup>18</sup>	NS	No	No	No	NA	NA	Yes	No	No	No	No
Rachel JM, 1988 <sup>19</sup>	NS	No	No	NS	NA	NA	Yes	No	No	No	No
Freedman J, 1984 <sup>32</sup>	NS	NS	No	No	NA	NA	Yes	No	Yes	No	No
Kakaiya RM, 1984 <sup>10</sup>	Yes	NS	No	Yes	NA	NA	Yes	No	Yes	No	No
Brand A, 1978 <sup>33</sup>	NS	NS	No	No	NA	NA	Yes	No	No	No	No
<b>Retrospective</b>											
Wiita AP, 2012 <sup>20</sup>	Yes	Yes	No	Yes	NA	NA	Yes	No	No	No	No

Levin MD, 2004 <sup>21</sup>	Yes	Yes	No	Yes	NA	NA	Yes	No	Yes	No	Yes
Gelb AB, 1997 <sup>22</sup>	NS	No	No	No	NA	NA	Yes	No	No	No	No
Kohler M, 1996 <sup>23</sup>	Yes	NS	No	Yes	NA	NA	Yes	No	NS	No	No
Sintnicolaa s K, 1996 <sup>24</sup>	Yes	Yes	No	Yes	NA	NA	Yes	No	NS	No	Yes
Gates K, 1994 <sup>25</sup>	Yes	NS	No	Yes	NA	NA	Yes	No	No	No	No
Chow MP, 1991 <sup>34</sup> and 1992 <sup>26</sup>	Yes	NS	No	Yes	NA	NA	Yes	No	NS	NS	No
McFarland JG, 1987 <sup>35</sup>	NS	NS	No	No	NA	NA	Yes	No	Yes	No	No
Heal JM,	Yes	Yes	No	Yes	NA	NA	Yes	No	NS	No	No

1987 <sup>27</sup>											
Kickler TS, 1985 <sup>36</sup>	NS	No	No	No	NA	NA	Yes	No	Yes	No	No
Ware R, 1984 <sup>37</sup>	NS	NS	No	Yes	NA	NA	Yes	No	Yes	No	No
Yam P, 1984 <sup>28</sup>	NS	NS	No	Yes	NA	NA	Yes	No	Yes	No	No
Kickler TS, 1983 <sup>29</sup>	NS	No	No	Yes	NA	NA	Yes	No	NS	No	No
<b>Prospective / Retrospective</b>											
Rebulla P, 2004 <sup>30</sup>	Yes	Yes	No	Yes	NA	NA	Yes	No	Yes	No	No
Skogen B, 1995 <sup>38</sup>	NS	NS	No	No	NS	NA	Yes	No	Yes	No	No
Moroff G, 1992 <sup>7</sup>	Yes	NS	No	Yes	NA	NA	Yes	No	No	No	No

Lane D, 1990 <sup>39</sup>	NS	Yes	No	No	NA	NA	Yes	No	No	No	No
Bowen TJ, 1986 <sup>40</sup>	NS	NS	No	Yes	NA	NA	Yes	No	Yes	No	No
Filip DJ, 1976 <sup>41</sup>	NS	NS	No	No	NA	NA	Yes	No	Yes	No	No
* Quality control measures for the collection of data and laboratory tests, e.g. accuracy and repeatability of observers, calibration and random calibration and accuracy of instruments, checks for errors in data recording.											

**Table S3. Estimates of Screening Tests in Diagnostic Accuracy Studies**

First Author, Year	Number of XMs Evaluated	XM Method	Patient Factors Eliminated	% Negative XMs Transfused	Sensitivity	Specificity	Negative Predictive Value	Positive Predictive Value	Accuracy (TP + TN / TP + TN + FP + FN)	Variability of Diagnostic Accuracy	Test Reproducibility
Sayed D, 2011 <sup>14</sup>	60	Flow PSIFT	None	NS	NS	NS	58%	NS	NS	NS	NS
Ogden DM, 1993 <sup>15</sup>	I: 143 (all patients) II: 105 (patients without nonimmune factors)	LAA	Group II only: Fever, Infection, DIC, Hemorrhage	79% 77% (33% of Group I XMs were compatible; 88% vs. 26% for those without and with, platelet-reactive	62% 72%	99% 99%	84% 89%	96% 96%	87% 91%	NS	CV within run: 6.2% CV between runs: 6.3%

				antibodies)							
O'Connell BA, 1990 <sup>16</sup>	964 417	ELISA SPRCA	Splenomegaly , Infection, DIC, Hemorrhage	24% 15% (21% XM'd units compatible)	NS	NS	30% 57%	NS	NS	NS	NS
Freedman J, 1988, <sup>31</sup> 1989 <sup>17</sup>	48 48 56 61 48	LCT ELISA PSIFT PRAT LCT+PRAT	Splenomegaly , Fever, Hemorrhage	NS	62% 28% 40% 79% 93%	79% 84% 81% 67% 47%	NS	NS	71% 44% 55% 71%	Concordance: PRAT vs. LCT 48% PRAT vs. PSIFT 59% PRAT vs. ELISA 40% PSIFT vs. LCT 44% PSIFT vs. ELISA 57%	Reproducibility with strong antibodies: PRAT 95% PSIFT 90% LCT 100% vs. with weak antibodies: PRAT 80% PSIFT 70%

										ELISA vs. LCT 60%	LCT 90%
Kickler TS, 1988 <sup>18</sup>	38	PRAT	Splenomegaly , Sepsis, DIC  (32% XM'd units compatible)	58%	88%	95%	91%	94%	92%	NS	NS
Rachel JM, 1988 <sup>19</sup>	I: 67 (all patients)  II: 32 (subset without nonimmune factors)	SPRCA	Group II only:  Splenomegaly , Fever, Sepsis, DIC, Hemorrhage	66%  66%  (17% XM'd units compatible)	68%	94%	77%	91%	82%	NS	NS
Freedman J, 1984 <sup>32</sup>	47	IgG/C3 PRAT	Splenomegaly , Fever, Hemorrhage	55% (on average, 58% XM'd units compatible)	90%	89%	92%	86%	89%	NS	NS
Kakaiya	43	ELISA  Microscopy PSIFT	None after	63%	48%	78%	52%	75%	60% /	NS	NS

RM, 1984 <sup>10</sup>	33 32	LCT	refractoriness demonstrated in absence of: Splenomegaly , Fever, Sepsis, DIC, Hemorrhage	70% 84%	39% 24%	80% 100%	52% 41%	70% 100%	81% 58% / 73% 50% / 70% (All patients. / subset without nonimmun e factors)		
Brand A, 1978 <sup>33</sup>	82	Microscopy PSIFT	Sepsis, DIC	72%	79%	100%	90%	100%	93%	NS	NS
Wiita AP, 2012 <sup>20</sup>	443	SPRCA	None	(on average, 41% XM'd units compatible)	NS	NS	41%	NS	NS	NS	NS
Levin MD,	1-hr : 184	Flow PSIFT	None	86%	18%	89%	60%	54%	59%	1-hr concordance	NS

2004 <sup>21</sup>	16-hr: 173			85%	18%	87%	64%	46%	61%	with flow PSIFT: in vivo PSIFT 81%, panel PSIFT 82%, ELISA 80%	
Gelb AB, 1997 <sup>22</sup>	475	SPRCA	None	31%  (on average, 60% XM'd units compatible)	NS	NS	51%	NS	NS	NS	NS
Kohler M, 1996 <sup>23</sup>	123 121 123	Flow PSIFT Flow LIFT LCT	Splenomegaly , Sepsis, DIC	85% 87% 87%	70% 33% 20%	90% 88% 88%	97% 94% 93%	39% 19% 12%	89% 84% 82%	PSIFT 95% sensitivity / 96% specificity vs. MAIPA, PSIFT 71% sensitivity / 78% specificity vs. panel LCT, LIFT 73% sensitivity	NS

										/ 92% specificity vs. panel LCT	
Sintnicolaas K, 1996 <sup>24</sup>	I: 104 (all patients)	Flow PSIFT	None after refractoriness demonstrated in absence of: Splénomegaly , Fever, Sepsis, DIC, Hemorrhage	72%	46%	81%	75%	55%	69%	NS	NS
	II: 82 (subset without nonimmune factors)		NS	NS	NS	81%	43%	NS	NS	NS	
	III: 22 (subset with nonimmune factors)		NS	NS	NS	50%	100%	NS	NS	NS	
Gates K, 1994 <sup>25</sup>	32	Flow PSIFT	Splénomegaly , Fever, Sepsis, DIC, SOS/VOD,	56%	60%	83%	56% (73% for samples with low	86% (89% for samples with low	69%	With PRA>35%: PPV 92%, NPV 62%, Accuracy 80%	NS

			Hemorrhage				background d)	background d)			
Chow MP, 1991 <sup>34</sup>	82	LCT Microscopy PSIFT	None	75% 73%	93% 93%	100% 96%	98% 97%	100% 90%	98% 95%	NS	NS
McFarland JG, 1987 <sup>35</sup>	35 of 55 1- hr & 34 of 53 24-hr without nonimmune factors	PRAT all PRAT subset PSIFT LCT <sup>51</sup> Cr release	None	<u>1-h/24-h</u> 49%/47% 54%/47% NS NS NS	<u>1-h/24-h</u> 65%/68% 75%/69% 40%/31% 24%/30% 12%/10%	<u>1-h/24-h</u> 67%87% 73%/100 % 93%/88% 73%/88% 100%/100 %	<u>1-h/24-h</u> 54%/52% 69%/50% NS NS NS	<u>1-h/24-h</u> 71%/93% 79%/100% NS NS NS	<u>1-h/24-h</u> 65%/74% 74%/76% 63%/44% 47%/45% 48%/32%	NS	Mean CV of PRAT 14.5% ±6.3%
Heal JM, 1987 <sup>27</sup>	222	ELISA	None	76%	33%	84%	57%	67%	59%	NS	NS
Kickler TS, 1985 <sup>36</sup>	1-hr : 230 18-24-h: 151	PRAT	Splenomegaly , Sepsis,	60% 54%	86% 82%	84% 92%	92% 83%	73% 91%	84% 87%	NS	NS

			Infection, DIC								
Ware R, 1984 <sup>37</sup>	68	PRAT  Microscopy  PSIFT	Splenomegaly  , Sepsis,  Hemorrhage,  'Collagen vascular disease'	40%  37%	86%  84%	84%  72%	78%  72%	90%  84%	85%  79%	NS	NS
Yam P, 1984 <sup>28</sup>	110	PRAT	Splenomegaly  , Fever, Sepsis	NS	73%	95%	87%	87%	NS	NS	PRAT CV with positive controls 8-13%
Kickler TS, 1983 <sup>29</sup>	1-hr : 89 20-hr: 56 1-hr : 63	PRAT  PRAT  LCT	Splenomegaly  , Sepsis, DIC	62%  55%  76%	96%  96%  27%	86%  100%  77%	98%  97%  77%	74%  100%  27%	89%  98%  65%	NS	NS
Rebulla P, 2004 <sup>30</sup>	569	SPRCA	None	NS	NS	NS	68%	NS	NS	NS	NS
Skogen B, 1995 <sup>38</sup>	Gr I : 8 Gr II :23	Flow PSIFT	Group III  only: Sepsis,	78%  100%	81%  0%	96%  100%	94%  88%	87%  -	93%  88%	NS	NS

	Gr III : 13		Fever, Hemorrhage	100%	0%	100%	40%	-	40%		
Bowen TJ, 1986 <sup>40</sup>	177 101 80	LCT Microscopy PSIFT ELISA	None	87 61 81	54 62 28	97 69 84	90 84 80	83 41 33	89 67 71	NS	NS
Filip DJ, 1976 <sup>41</sup>	53 47 62 44 (64 overall)	LCT SRA PF3 Aggregometry	Splenomegaly , Fever, Sepsis, DIC, Hemorrhage, 'Other processes accelerating platelet turnover'	66% 68% 82% 86%	57% 40% 24% 17%	83% 77% 88% 88%	71% 53% 57% 61%	72% 67% 64% 50%	72% 57% 58% 59%	NS	NS

## APPENDIX

Database: Ovid MEDLINE(R) <1946 to November Week 3 2012>, Embase <1974 to 2012

December 18>

Search Strategy:

- 1 exp platelet transfusion/ (14232)
- 2 blood transfusion.mp. (168139)
- 3 limit 2 to yr="1966-1991" (56813)
- 4 blood platelets.mp. (71381)
- 5 limit 4 to yr="1966-1993" (41257)
- 6 blood component transfusion.mp. (2933)
- 7 limit 6 to yr="1992-1993" (530)
- 8 transfusion.mp. (258167)
- 9 4 and 8 (3872)
- 10 limit 9 to yr="1972-1993" (1662)
- 11 "platelet transfusion\*".mp. (10686)
- 12 1 or 3 or 5 or 7 or 10 or 11 (112073)
- 13 exp HLA antigens/ (142446)
- 14 histocompatibility.mp. (190437)
- 15 limit 14 to yr="1970-1972" (7066)
- 16 histocompatibility antigens.mp. (49549)
- 17 limit 16 to yr="1973-1974" (1911)
- 18 exp antigens, human platelet/ (2744)
- 19 antigens.mp. (759346)
- 20 limit 19 to yr="1966-1979" (94180)
- 21 isoantigens.mp. (9599)
- 22 limit 21 to yr="1976-1991" (4167)
- 23 platelet-specific antigen\$.tw. (328)
- 24 antigen\$, platelet-specific.tw. (8)
- 25 platelet alloantigen\$.tw. (451)
- 26 alloantigen\$, platelet.tw. (3)
- 27 human platelet antigen\$.tw. (745)
- 28 (HLA or HL-A or HPA antigen\$).tw. (172226)
- 29 or/13-28 (959932)
- 30 exp "Blood Grouping and Crossmatching"/ (7739)
- 31 typing, blood.tw. (27)
- 32 blood crossmatching.tw. (14)
- 33 blood typing.tw. (988)
- 34 blood grouping.tw. (1320)
- 35 grouping, blood.tw. (17)

36 blood grouping.mp. and crossmatching.tw. (164)  
37 crossmatching, blood.tw. (25)  
38 crossmatch.tw. (3548)  
39 or/30-38 (12217)  
40 exp thrombocytopenia/ (142112)  
41 blood group incompatibility.mp. (9295)  
42 (alloimmunity or alloimmunization).tw. (4954)  
43 (refractory or refractoriness).tw. (180309)  
44 or/40-43 (327029)  
45 12 and 29 and 44 (2644)  
46 exp thrombocytopenia, neonatal alloimmune/ (414)  
47 "neonatal alloimmune thrombocytopenia".tw. (1119)  
48 (FNAIT or NAIT).tw. (481)  
49 or/46-48 (1319)  
50 45 not 49 (2328)  
51 luminex.tw. (4745)  
52 elisa.tw. (232853)  
53 maipa.tw. (509)  
54 sprca.tw. (63)  
55 lymphocytotoxic.tw. (2422)  
56 or/51-55 (239636)  
57 39 or 56 (251015)  
58 50 and 57 (365)  
59 editorial.mp. (816536)  
60 58 not 59 (365)  
61 case report.mp. (2108616)  
62 60 not 61 (342)  
63 case reports.mp. (1689980)  
64 62 not 63 (315)  
65 letter.mp. (1637209)  
66 64 not 65 (314)  
67 letters.mp. (76702)  
68 66 not 67 (314)  
69 abstract.mp. (1922361)  
70 68 not 69 (286)  
71 abstracts.mp. (66142)  
72 70 not 71 (286)  
73 review.mp. (4603357)  
74 72 not 73 (252)  
75 review article.mp. (18989)  
76 74 not 75 (252)  
77 limit 76 to English language (220)  
78 limit 77 to humans (196)  
79 remove duplicates from 78 (146)

Collaborators

The International Collaboration for Guideline Development, Implementation and Evaluation  
for Transfusion Therapies (ICTMG)

Shubha Allard MD, FRCP, FRCP(Path), University of London, UK; David Anderson MD, MSc, FRCPC, Dalhousie University, Halifax, Canada; Brian Berry, University of British Columbia, Canada; Jeannie Callum, BA, MD, FRCPC, CTBS, University of Toronto, Canada; Celso Bianco, MD, America's Blood Centers; Anne Eder MD, PhD, American Red Cross; Dean Fergusson MHA, PhD, University of Ottawa, Canada; Mark Fung, MD, PhD; Andreas Greinacher, MD, University of Greifswald, Germany; Heather Hume, MD, FRCPC, Université de Montréal, Canada; Catherine Moltzan, MD, FRCPC, University of Manitoba, Canada; Susan Nahirniak, MD, FRCPC, University of Alberta, Canada; Michael Murphy, MD, University of Oxford, UK; Katerina Pavenski, MD, FRCPC, University of Toronto, Canada; Joanne Pink, MD, Australian Red Cross Blood Services; Ben Saxon, MBBS, FRACP, FRCPA, Australian Red Cross Blood Service, Australia; Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth-Hitchcock Medical Center; Alan T. Tinmouth, MD, FRCPC, MSc, University of Ottawa, Canada; Simon J. Stanworth, MA, MRCP, DPhil, FRCPATH, University of Oxford, UK; Lucinda Whitman, BSc, MD, FRCPC, Memorial University Canada; Veerle Compernelle, Belgian Red Cross-Flanders, Belgium; Ralph Vassallo, MD, American Red Cross; Erica Wood, MBBS, FRACP, FRCPA, Monash University, Australia.